CANN GROUP LIMITED

ASX ANNOUNCEMENT

30 June 2022

TGA GMP Manufacturing Licence granted for Mildura facility

30 June 2022 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) is pleased to announce that the Therapeutic Goods Administration (**TGA**) has granted Cann a GMP licence to manufacture therapeutic goods which includes GMP testing at its Mildura facility (**Mildura GMP Licence**).

In combination with the licences and permits issued by the Office of Drug Control (**ODC**) earlier this year, the Mildura GMP Licence enables Cann to manufacture Active Pharmaceutical Ingredients (**API**) and hard capsules, and to conduct GMP-approved activities at the facility's existing chemistry and microbiology laboratories.

This will allow the Company to produce API at the facility, manufacture Satipharm capsules for human therapeutic use, and perform in-house chemical, physical, and microbiological tests to demonstrate that products meet local and overseas regulatory requirements.

While manufacturing and testing activities had already commenced at Mildura following the licences and permits issued by the ODC and the Victorian Department of Health, the Mildura GMP Licence will allow medicinal cannabis products manufactured at Mildura to be made available to patients via the TGA's approved access pathways in Australia and (subject to approvals) for export markets.

Cann's CEO, Mr Peter Crock, said "GMP licencing is the regulatory capstone of the Mildura facility, allowing us to cultivate, extract, manufacture, test, and supply finished products entirely in-house. With the licence in place, we can now add additional GMP capabilities in response to market demands."

Left to right: aerial view of Cann's Mildura facility; staff produce our patented microspheres (for use in Satipharm capsules) in one of the GMP suites.

Cann Group Limited (ACN 603 949 739)
4 Research Avenue, Bundoora, VIC 3083 Australia
Ph: +61 3 9095 7088

Authorised for release by the Board of Directors, Cann Group Limited.

For all media enquiries please contact:

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

For all other information please contact:

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouplimited.com

Deborah Ambrosini
CFO
Cann Group Limited
+61 3 9095 7088
deborah.ambrosini@canngrouplimited.com

About Cann Group
Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved export markets. Cann has established research, cultivation and GMP manufacturing facilities in Melbourne and a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group's leading position in plant genetics, breeding, extraction, analysis and production techniques supports its objective to supply high quality, safe medicinal cannabis for a range of diseases and medical conditions. Cann's product portfolio incorporates its proprietary Satipharm delivery system for cannabinoids.
Learn more at: www.canngrouplimited.com | www.satipharm.com